Dr.john P. Chaney L.l.c. Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 136a Us Highway 14a, Central City, SD 57754 Phone: 605-584-1500 Fax: 605-722-1188 |
News Archive
Two studies published in a recent issue of Cell Medicine report on the therapeutic efficacy of stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).
ValenTx, Inc., announced today the closing of a $22 million Series B Preferred Stock financing. The round was led by SV Life Sciences and joined by Covidien Ventures, as well as all the Company's existing venture capital investors: Sapient Capital, EDF Ventures, Kaiser Permanente Ventures, Affinity Capital Partners, and TGap Ventures.
AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.
Venuprasad Poojary, PhD, an associate investigator at Baylor Institute for Immunology Research (BIIR), part of Baylor Scott & White Research Institute, reported this week in the journal Nature Immunology the role of a key protein in the regulatory pathway that is involved in limiting colon inflammation and tumor growth.
› Verified 9 days ago